International Journal of Molecular Sciences (Apr 2024)

Development of Novel Peptidyl Nitriles Targeting Rhodesain and Falcipain-2 for the Treatment of Sleeping Sickness and Malaria

  • Carla Di Chio,
  • Josè Starvaggi,
  • Noemi Totaro,
  • Santo Previti,
  • Benito Natale,
  • Sandro Cosconati,
  • Marta Bogacz,
  • Tanja Schirmeister,
  • Jenny Legac,
  • Philip J. Rosenthal,
  • Maria Zappalà,
  • Roberta Ettari

DOI
https://doi.org/10.3390/ijms25084410
Journal volume & issue
Vol. 25, no. 8
p. 4410

Abstract

Read online

In recent decades, neglected tropical diseases and poverty-related diseases have become a serious health problem worldwide. Among these pathologies, human African trypanosomiasis, and malaria present therapeutic problems due to the onset of resistance, toxicity problems and the limited spectrum of action. In this drug discovery process, rhodesain and falcipain-2, of Trypanosoma brucei rhodesiense and Plasmodium falciparum, are currently considered the most promising targets for the development of novel antitrypanosomal and antiplasmodial agents, respectively. Therefore, in our study we identified a novel lead-like compound, i.e., inhibitor 2b, which we proved to be active against both targets, with a Ki = 5.06 µM towards rhodesain and an IC50 = 40.43 µM against falcipain-2.

Keywords